Aciclovir Injection 250 mg / 500 mg

Gastrointestinal: Nausea and vomiting have been reported.

Haematological: Decreases in haematological indices (anaemia, thrombocytopenia, leucopenia).

Hypersensitivity and Skin: Rashes including photosensitivity, urticaria, pruritus, fevers and rarely dyspnoea, angioedema and anaphylaxis. Severe local inflammatory reactions sometimes leading to breakdown of the skin have occurred when formulations of aciciovir for intravenous use have been inadvertently infused into extravascular tissues.

Kidney: Rapid increases in blood urea and creatinine levels may occasionally occur in patients given aciclovir for infusion. This is believed to be related to peak plasma levels and the state of hydration of the patient. To avoid this effect the drug should not be given as an intravenous bolus injection but by slow infusion over a one hour period. Adequate hydration of the patient should be maintained. Renal impairment developing during treatment with aciclovir for infusion usually responds rapidly to rehydration of the patient and/or dosage reduction or withdrawal of the drug. Progression to acute renal failure, however, can occur in exceptional cases.

Liver: Reversible increases in bilirubin and liver-related enzymes. Hepatitis and jaundice have been reported on very rare occasions.